Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Women's Health

CME

Targeted Therapies for Ovarian Cancer

Targeted therapy for ovarian cancer is rapidly evolving field.
CME credit is no longer available for this conference.

Course Authors

Frederick Sweet, Ph.D.

Frederick Sweet, Ph.D. is Professor of Reproductive Biology in Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri.

Dr. Sweet reports no commercial conflicts of interest.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss the diverse concepts that constitute targeted therapy

  • Describe recent basic and clinical progress from research on these novel therapies

  • Discuss how near or far we are from having more effective new therapies for ovarian cancer "just around the corner."

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Sex-Related Differences in Addiction

While more men use and are addicted to drugs, women who become addicted progress faster through the landmark stages from initial use to dependence.
Authors: Jill B. Becker, Ph.D. and Jillian E. Hardee, Ph.D.
Estimated Time: 1 Hour
View Course
More

Caring for Women and Their Families: The Essential Role of Reproductive Rights

Medical professionals must manage reproductive rights in a highly politicized environment.
Authors: Nada L. Stotland, M.D., M.P.H.
Estimated Time: 1 Hour
View Course
More

Current and Emerging Therapies for Vulvo-vaginal Atrophy

Vulvo-vaginal atrophy in peri- and post-menopausal women is caused by declining, then deficient estrogen levels, and affects more than half of otherwise healthy women over age 60.
Authors: Nancy A. Phillips, M.D., and Gloria A. Bachmann, M.D.
Estimated Time: 1 Hour
View Course
More

Current Management of Endometriosis

Endometriosis remains one of the most complex pathologies faced by OBGYNs and primary care physicians.
Authors: Kenan Omurtag, M.D., and Amber R. Cooper, M.D., M.S.C.I.
Estimated Time: 1 Hour
View Course
More

Endometrial Cancer

Endometrial carcinoma is the most common female genital tract neoplasm in the United States.
Authors: Yevgeniya Ioffe, M.D., and Israel Zighelboim, M.D.
Estimated Time: 1 Hour
View Course
More

Evaluation and Treatment of Polycystic Ovary Syndrome

Androgen Excess (AE)-PCOS Society recommended that PCOS be defined by clinical/biochemical hyperandrogenism.
Authors: Daniel A. Dumesic, M.D., Mark O. Goodarzi, M.D., Ph.D., Gregory D. Chazenbalk, Ph.D., David Geller, M.D., and David H. Abbott, Ph.D.
Estimated Time: 1 Hour
View Course
More